Global NASH Congress 2018
In-Person Event
Feb 26 - 27, 2018
London, England, GB
OVERVIEW
Global Nonalcoholic Steatohepatitis (NASH) Congress is organized by Global Engage Ltd and will be held during Feb 26 - 27, 2018 at London Heathrow Marriott Hotel, London, England, United Kingdom. The target audience for this medical event is Hepatologists, gastroenterologists.
Course description :
This two-day conference will facilitate collaboration between senior representatives from industry, hospitals, universities and regulators.
Attracting experts working in all areas of nonalcoholic steatohepatitis, the conference will examine the latest research and development in pathogenesis, diagnosis and treatment of the disease.
An increasing number of people are being diagnosed with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) each year, and the primary method of treatment is weight loss. With no approved medicines on the market, the drug development race is intensifying. The pathogenesis of NASH is still not fully understood, and definitive diagnostic methods are invasive, so development has been slow.
There are, however, promising developments in research that will hopefully bolster drug development and other methods of treatment. Examples of such developments include improved in vivo liver models, non-invasive diagnostic biomarkers and a better understanding of the disease’s mechanisms. This year’s congress will focus on these exciting advancements, as well as on the challenges of preclinical and clinical research in NASH. There will also be a session on business development/regulation and a showcase of the most promising therapeutics in development.
Extended networking time and small group roundtable discussions will provide ample opportunity for idea sharing and cooperation between the stakeholders in attendance.
40+ speakers will present across topics such as molecular heterogeneity of NAFLDs in humans, lifestyle intervention, and autotaxin as a potential drug target for NASH. Additionally, the US FDA and European Medicines Agency will give regulatory talks.
Additional details will be posted as soon as they are available.
Course description :
This two-day conference will facilitate collaboration between senior representatives from industry, hospitals, universities and regulators.
Attracting experts working in all areas of nonalcoholic steatohepatitis, the conference will examine the latest research and development in pathogenesis, diagnosis and treatment of the disease.
An increasing number of people are being diagnosed with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) each year, and the primary method of treatment is weight loss. With no approved medicines on the market, the drug development race is intensifying. The pathogenesis of NASH is still not fully understood, and definitive diagnostic methods are invasive, so development has been slow.
There are, however, promising developments in research that will hopefully bolster drug development and other methods of treatment. Examples of such developments include improved in vivo liver models, non-invasive diagnostic biomarkers and a better understanding of the disease’s mechanisms. This year’s congress will focus on these exciting advancements, as well as on the challenges of preclinical and clinical research in NASH. There will also be a session on business development/regulation and a showcase of the most promising therapeutics in development.
Extended networking time and small group roundtable discussions will provide ample opportunity for idea sharing and cooperation between the stakeholders in attendance.
40+ speakers will present across topics such as molecular heterogeneity of NAFLDs in humans, lifestyle intervention, and autotaxin as a potential drug target for NASH. Additionally, the US FDA and European Medicines Agency will give regulatory talks.
Additional details will be posted as soon as they are available.
KEY DATES
26 Feb, 2018
Event Start Date
27 Feb, 2018
Event End Date
SPECIALITIES
GastroenterologyRenal Medicine Disease and HypertensionHepatologySUGGESTED HOTELS
CONFERENCE VENUE
London Heathrow Marriott HotelRELATED CONFERENCES & LIVE WEBINARS
Quick Links